News Room

Stay up to date with our latest news and developments.

News Room

Stay up todate with our latest news and developments.

Dr. Axel Mescheder Steps Down as Chief Medical Officer

APTA Therapeutics GmbH would like to extend its warmest thanks to Dr. Axel Mescheder for his outstanding leadership, dedication and foresight in advancing the clinical development of rovunaptabin for the treatment of post-acute viral syndrome. Although Dr. Mescheder is stepping down from his role as Chief Medical Officer, APTA hopes that he will remain closely involved in the further development of rovunaptabin.

READ MORE

US Patent Grant Strengthens APTA’s Pipeline of Autoantibody-Targeting Aptamers

We are pleased to announce that the United States Patent and Trademark Office (USPTO) has officially granted APTA Therapeutics a US patent 12,630,828 within a pivotal patent family covering the design and medical use of all functional aptamer compounds targeting autoantibodies as well as the use of a novel algorithm to identify elements of structural commonality. Further patents have already been granted and will be granted in the future to generate broad patent protection for this key invention, in the US and worldwide.

READ MORE

Collaboration with Fraunhofer SCAI

APTA Therapeutics is pleased to announce that it has entered into a collaboration with the Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) to implement state-of-the-art data-and knowledge-driven methods to better define patient recruitment for the upcoming clinical trials in post-viral infectious diseases.

READ MORE

Agreement with CIBIT

APTA Therapeutics is pleased to announce that it has entered into an agreement with Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT) to support an Investigator Initiated Trial with rovunaptabin in patients with long COVID.

READ MORE